News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
TMX Newsfile
NEWS
IN THE PRESS
Press Releases
Hemostemix Announces Financing Plans for VesCell(TM) Treatment
August 28, 2025
·
7 min read
Press Releases
Nextleaf Reports Third Quarter FY25 Results Including Fourth Consecutive Profitable Quarter
August 28, 2025
·
7 min read
Press Releases
Therma Bright Proposes to Amend Certain Warrants
August 28, 2025
·
3 min read
Press Releases
OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025
August 28, 2025
·
3 min read
Press Releases
MustGrow Announces Record Q2-2025 Results: $2.8 Million Revenue and 20.9% Gross Profit Margin for the Quarter
August 28, 2025
·
5 min read
Press Releases
Theralase(R) Releases 2Q2025 Financial Statements
August 27, 2025
·
1 min read
Press Releases
PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx(TM)), Aligned with FDA’s CNPV National Priority Initiative
August 27, 2025
·
6 min read
Press Releases
Hemostemix’s Boots on the Ground in Florida
August 26, 2025
·
1 min read
Press Releases
Izotropic Announces Non-Brokered Private Placement & Extends Warrants
August 26, 2025
·
4 min read
Press Releases
NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders
August 26, 2025
·
14 min read
15 Toronto St., Suite 601 Toronto ON M5C 2E3 US
Tel: 416-806-1750
Visit website
Email Us